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Abstract
Background: Ukraine has the highest HIV prevalence (1.6%) and is facing the fastest growing epidemic in Europe.
Our objective was to describe the clinical, immunological and virological characteristics, treatment and response in
vertically HIV-infected children living in Ukraine and followed from birth.
Methods: The European Collaborative Study (ECS) is an ongoing cohort study, in which HIV-1 infected pregnant
women are enrolled and followed in pregnancy, and their children prospectively followed from birth. ECS
enrolment in Ukraine started in 2000 initially with three sites, increasing to seven sites by 2009.
Results: A total of 245 infected children were included in the cohort by April 2009, with a median age of 23
months at most recent follow-up; 33% (n = 77) had injecting drug using mothers and 85% (n = 209) were infected
despite some use of antiretroviral prophylaxis for prevention of mother-to-child transmission. Fifty-five (22%)
children had developed AIDS, at a median age of 10 months (IQR = 6-19). The most prevalent AIDS indicator
disease was Pneumocystis jiroveci pneumonia (PCP). Twenty-seven (11%) children had died (median age, 6.2
months). Overall, 108 (44%) children had started highly active antiretroviral treatment (HAART), at a median 18
months of age; median HAART duration was 6.6 months to date. No child discontinued HAART and 92% (100/108)
remained on their first-line HAART regimen to date. Among children with moderate/severe immunosuppression,
36% had not yet started HAART. Among children on HAART, 71% (69/97) had no evidence of immunosuppression
at their most recent visit; the median reduction in HIV RNA was 4.69 log10 copies/mL over a median of 10 months
treatment. From survival analysis, an estimated 94%, 84% and 81% of children will be alive and AIDS-free at 6, 12
and 18 months of age, respectively. However, survival increased significantly over time: estimated survival rates to
12 months of age were 87% for children born in 2000/03 versus 96% for those born in 2004/08.
Conclusion: One in five children had AIDS and one in ten had died. The half of children who received HAART has
responded well and survival has significantly improved over time. Earlier diagnosis and prompt initiation of HAART
remain key challenges.
Background
Prevalence of HIV infection in Ukraine is 1.6% overall,
with antenatal prevalence of 0.52%, the highest in
Europe and the country is facing one of the fastest grow-
ing epidemics in the world [1]. According to UNAIDS
estimates, 1.5 million people will be living with HIV/
AIDS in Ukraine by 2010, two-thirds of whom will be of
reproductive age [2]. The number of HIV infected preg-
n a n tw o m e nd e l i v e r i n gi nU k r a i n eh a sb e e ni n c r e a s i n g
annually, reaching 5000 in 2007 [3]. In Ukraine, the
national Prevention of Mother to Child Transmission
(PMTCT) Programme was implemented in 2001 [2].
This programme has been successful with MTCT rates
declining from above 25% in 2001 to 7% in 2006 [1,4]. In
2007 the government implemented more comprehensive
HIV/AIDS programmes and policies to scale up access to
prevention, diagnosis and treatment services nationally,
but antiretroviral therapy (ART) coverage for adult popu-
lation remains low, with 35% of individuals with
advanced HIV infection receiving ART in 2007 [5,6].
In children, recent studies have demonstrated that
early diagnosis of HIV infection followed by early
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bidity and mortality and has resulted in substantially
improved survival [7-10]. This, together with the higher
risk of clinical progression for vertically-infected infants
compared with older children and adults, due to high
HIV-1 RNA viral load (VL) and immature immune sys-
tems [7-9,11-16], reflects the essential need for scaling
up access to paediatric HIV care and treatment.
Few data are available on the natural and treated his-
tory of vertically infected children in Eastern Europe.
This information, including treatment patterns, clinical,
immunological and virological impact of treatment and
long-term outcomes of HIV infection in children, is
important to achieve a better understanding of disease
progression in this setting and for health care planning
and decision-making related to therapeutic strategies.
Our objective was to describe the clinical, immunologi-
cal and virological characteristics, treatment and
response in vertically-infected children living in Ukraine
and followed from birth in an ongoing cohort study.
Methods
The European Collaborative Study (ECS) is an ongoing
cohort study, in which HIV-1 infected pregnant women
are enrolled and followed in pregnancy, and their children
prospectively followed from birth. The ECS was estab-
lished in 1985 in Western Europe and centres from
Ukraine first joined in 2000. ECS enrolment in Ukraine
started with three sites (Odesa, Mykolaiv and Simferopol),
increasing to six sites in 2006 (addition of Kyiv, Donetsk
and Mariupol) and with the addition of Kryvyj Rih in
2009. All pregnant women are screened for HIV-1 infec-
tion at first antenatal visit during their pregnancy (routine,
universal opt-out system) with repeat testing in the third
trimester for women testing negative. A policy for rapid
HIV testing during labour for women with undocumented
HIV status started in 2003 for those not having antenatal
care. Pregnant women diagnosed with HIV infection
before pregnancy, during pregnancy or intrapartum are
offered to participate in ECS study, with informed consent.
Standard questionnaires which are coded anonymised are
used for collection of pregnancy, delivery and follow-up
data. Infants are followed up at HIV/AIDS Centres until a
diagnosis is made. HIV-1 infected children are then fol-
lowed up ideally at least twice a year. Infected infants were
diagnosed based on persistence of HIV antibody beyond
age 18 months up until the start of 2006; subsequently,
early diagnosis of HIV-exposed infants with DNA PCR
testing was introduced nationwide, with facilities in three
inter-regional laboratories. Data collected included mater-
nal clinical and sociodemographic status, PMTCT inter-
vention, delivery data, infant demographic and clinical
characteristics, ART, other prophylaxis and laboratory
markers of disease progression. Flow cytometry became
available in Odessa and Simferopol in 2004; Donetsk and
Kiev had this capacity from their first enrolments in
autumn 2006.
Definition of HIV-1 infection was based on the devel-
opment of AIDS and HIV-associated morbidity and
mortality, persistence of HIV antibody beyond 18
months of age or detectable virus in two or more blood
samples. CD4 counts were expressed as absolute counts,
which vary with age. Children were therefore assigned
to a Centres of Disease Control and Prevention (CDC)
immunological category on the basis of their age and
CD4 count at the time of each measurement. CDC
immunological categories are as follows: normal (CDC
immunological category 1), moderate immune suppres-
sion (category 2) and severe immune suppression (cate-
gory 3) [17,18]. HIV RNA levels were measured with a
lower limit of quantification of 400 copies/ml and thus
undetectable VL was defined as VL less than 400
copies/ml [10,19].
Statistical analysis
Kaplan-Meier survival analyses were carried out to esti-
mate the proportion of children progressing to death
and AIDS over time since birth (i.e. time of infection),
separately and as a compound outcome variable. In
addition, children born in 2000-2003 and in 2004-2008
were compared in terms of time to AIDS or death using
Kaplan-Meier plots and the log rank test.
Data were entered and managed in an Access database
using Microsoft Access XP (Redmond, WA, USA). Data
analyses were carried out using STATA, (STATA Version
10; STATA Corporation, College Station, Texas, USA).
Ethics approval
The ECS has been approved by the Great Ormond
Street Hospital for Children NHS Trust/Institute of
Child Health Ethics Committee.
Results
Maternal and infant characteristics and PMTCT
interventions
A total of 245 HIV-1 infected children were included in
t h ec o h o r tb yA p r i l2 0 0 9w i t ham e d i a na g eo f2 3
months (IQR, 14-46 months) at most recent follow-up
visit. Most mothers were Ukrainian nationals (240/245,
98%) and either married (97/241, 40%) or cohabiting
(101/241, 43%). Median maternal age at delivery was 27
years (IQR, 23-30) and for half of the mothers (n = 133)
this delivery was their first live birth. A large proportion
of mothers reported no specific risk factors for HIV
acquisition but of the 132 who did, 80% (n = 106) noted
sexual risk factors, of whom half also had an injecting
drug use (IDU) history (Table 1). Overall, 15 (6%)
infants had neonatal abstinence syndrome. The mothers
of nine (4%) infected children were known to have died.
Mahdavi et al. BMC Pediatrics 2010, 10:85
http://www.biomedcentral.com/1471-2431/10/85
Page 2 of 9A quarter (n = 63, 26%) of mothers had received no
antenatal antiretroviral (ARV) prophylaxis for PMTCT,
27% (n = 67) had received zidovudine (ZDV) monother-
apy, 20% (n = 50) intrapartum single dose nevirapine
(sdNVP) only, a quarter (n = 61) ZDV with sdNVP and
2% (n = 4) had received antenatal HAART. Most neo-
nates received ARV prophylaxis (Table 2) and thus the
majority of children (n = 209, 85%) were infected
despite the use of some PMTCT prophylaxis. Overall,
around a fifth of children were delivered preterm (i.e. <
37 weeks gestation) (Table 1) and median birth weight
was 2900 g (range, 1150-5000). The vast majority of
children were bottle fed (237/244, 97%) with breastfeed-
ing reported for seven children, three of whom were
breastfed for a month and two were breastfed for 12
and 24 weeks, respectively.
Coverage of infants with early virological diagnostic
testing in this cohort was low, reflecting the fact that
DNA PCR testing only became available in 2006: overall,
132 (54%) children had one or more DNA PCR tests
and of these, 18 (14%) received their first virological test
before age 4 months, 83 (63%) between 4-18 months
and 31 (23%) after 18 months. Among children born in
2007/08 with PCR tests carried out, 23% (n = 8/35)
tested before age of 4 months. Median age of children
at first PCR test was 12.5 months (range, 0-88 months).
Overall, median age of children at first DNA PCR test
was 12.5 months (range, 0-88 months). The remaining
113 children without DNA PCR test results were diag-
nosed on the basis of antibody testing (100, 41%) after
age 15-18 months or the development of AIDS (13, 5%).
Treatment
Nearly half of the children (n = 108, 44%) had started
highly active antiretroviral treatment (HAART) by their
most recent follow-up visit. Most had initiated HAART
within 2007 to 2009 (n = 91, 86%). The first-line
HAART regimens are shown in Figure 1 with ZDV
+3TC+LPV/r being the most common. Median age at
HAART initiation was 18 months (IQR, 9-45 months)
overall, but this decreased substantially over time, from
55 months for those born before 2004 to 9 months for
those born in 2007-2008. Of children born in 2006/09,
88% (39/44) started HAART at < 18 months of age, sub-
stantially more than those born in 2000/2 and in 2003/4
(17% [4/20] and 20% [10/50] respectively) (p < 0.001).
Median HAART duration at most recent follow-up was
6.6 months. No child had discontinued HAART and the
majority (n = 100, 92%) remained on their first-line
HAART regimen to date.
A total of 75 (31%) children had received prophylaxis
at any time during follow-up, mainly trimethoprim (n =
71, 95%), with 9 (4%) children had received isoniazid as
TB treatment/prophylaxis.
Table 1 Maternal and delivery characteristics
N (%)
Maternal risk factors for acquisition of HIV (n = 241)
IDU 24 (10)
Sexual 53 (22)
IDU & sexual 53 (22)
Other 2(0.8)
Not specified 107 (44)
Time of maternal HIV diagnosis (n = 239)
Before pregnancy 62 (26)
During pregnancy 134 (56)
At delivery 43 (18)
Mothers’ WHO clinical stage at enrolment (n = 213)
Stage 1 92 (43)
Stage 2 110 (52)
Stage 3 8 (4)
Stage 4 3 (1)
Mode of delivery (n = 245)
Vaginal 183 (75)
Emergency caesarean section 9 (3.5)
Elective caesarean section 53 (21.5)
Gestational age (n = 245)
< 34 weeks 17 (7)
34-36 26 (11)
≥ 37 202 (82)
Birth weight (n = 245)
< 2500 g 58 (24)
≥ 2500 g 187 (76)
Table 2 Children’s characteristics
N (%)
Sex (n = 241)
Female 121 (50)
Male 120 (50)
Care setting at most recent follow-up (n = 238)
Parental 196 (82)
Institutional 41 (17)
Adopted/Fostered 1 (0.4)
Neonatal prophylaxis regime (n = 245)
Only sdNVP 76 (31)
Only ZDV 52 (21)
ZDV + sdNVP 77 (31)
ZDV + 3TC ± sdNVP 4 (2)
None 36 (15)
Children’s WHO clinical stage at most
recent follow-up (n = 245)
Stage 1 120 (49)
Stage 2 49 (20))
Stage 3 27 (11)
Stage 4 49 (20)
Deaths 27 (11)
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Overall, 15.5% (38/245) of infants progressed to AIDS or
death in their first year of life. A total of 55 (22%) chil-
dren had developed AIDS by most recent follow-up, two
of whom had not received HAART. Median age of pro-
gression to AIDS was 10 months (IQR = 6-19). The
most prevalent AIDS indicator diseases were Pneumo-
cystis jiroveci pneumonia (PCP), recurrent severe bacter-
ial infection and HIV encephalopathy (Table 3). CD4
counts were available for 155 (63%) children, with a
total of 351 measurements by last follow-up. Median
age at first CD4 count measurement was 14.7 months.
HIV RNA measurements were available for 132 (54%)
children with 238 measurements in total to date.
Table 4 shows CDC immunological categories at most
recent follow-up stratified by age. Overall, three quarters
of children (111/155) showed no evidence of immune
suppression at this time, 17% (n = 27) had evidence of
moderate immune suppression and 11% (n = 17) were
severely immunosuppressed. Of the 44 children either
moderately or severely immuno-suppressed, 16 (36%)
had not received ART by their most recent follow-up
visit. A total of 27 (11%) children had died, at a median
age of 6.2 months (IQR 4-19); the most common
causes of death were septicaemia (n = 13) and pneumo-
nia (n = 8). Most (19, 75%) had progressed to AIDS
before their death, of whom 14 (74%) died in their first
year of life; 7 children died without receiving HAART.
The overall mortality rate was 4.29 deaths per 100
child-years of follow-up.
Response to treatment
Half of the children on HAART (53/108) had been
initiated on this recently and did not yet have a reported
VL after HAART initiation. Of the 55 children with VL
measurements available after HAART initiation, 71%
(n = 39) had achieved an undetectable VL to date. In 46
children on HAART with both pre and post HAART
VLs available, the median reduction in HIV-1 RNA was
4.69 (IQR 2.11-5.89) log10 copies/mL over a median
duration of 10 months treatment (IQR, 5-38). Of chil-
dren with a CD4 measurement available at HAART
initiation or within 12 weeks prior to initiation, 41%
(23/56) were either moderately (CDC immunological
category 2) (n = 15) or severely (CDC immunological
category 3) (n = 8) immunosupressed. Of the 97 (90%)
children on HAART with a CD4 measurement at their
most recent follow-up, 69 (71%) had no evidence of
immunosuppression.
From Kaplan-Meier survival analyses, an estimated
94%, 84% and 81% of children will be alive and AIDS-
free at 6, 12 and 18 months of age, respectively. A
further analysis of time to progression to AIDS alone
indicated that an estimated 4%, 13% and 17% of infected
children will have developed AIDS by 6, 12 and 18
months of age. A further survival analysis stratified by
calendar period indicated that progression to death
decreased significantly over time (p < 0.001) (Figure 2):
an estimated 87% and 84% of children born in 2000/03
survived to ages 12 and 18 months respectively, com-
pared with 96% and 95% for children born in 2004/08.
H o w e v e r ,t h e r ew a sl i t t l ec h a n g ei nA I D S - f r e es u r v i v a l
rates over time, with estimated AIDS-free survival rates
in children born in 2004/08 of 85% and 80% at 12 and
18 months versus 83% and 79% for those born in 2000/
03. Estimated AIDS-free survival was higher for children
who had never received HAART versus those who had,
at 89% and 86% versus 78% and 73% at 12 and 18
months of age, respectively.
Discussion
We have investigated the therapeutic management, dis-
ease progression and survival rate in a birth cohort of
Figure 1 Type of first line HAART regimen among 108 treated
children. Footnote: Other regimens: 3TC+ABC+LPV/r, ABC+ZDV
+ddI, ddI+ZDV+LPV/r, ZDV+3TC+EFV, D4T+ddI+NFV, D4T+3TC+NFV,
3TC+ddI+LPV/r
Table 3 Prevalence of AIDS indicator diseases among 55
children with AIDS
N (%)
Pneumocystis jiroveci pneumonia (PCP) 15 (27)
2+ severe bacterial infection within a 2-year period 13 (24)
HIV encephalopathy 9 (16)
Extra pulmonary m. tuberculosis infection 7 (13)
Opportunistic infection (unspecified) 6 (11)
HIV wasting syndrome 2 (4)
Weight loss > 10% of baseline 2 (3.5)
Candidiasis (oesophageal, bronchial or pulmonary) 1 (2)
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started HAART by their most recent follow-up visit,
with most of these children starting HAART recently
(since 2007). In addition to HAART, 31% of children
received prophylaxis and 4% received TB treatment.
Substantial immunological improvement among children
on HAART was evident and, among those with VL
measurements available post-initiation, nearly three-
quarters had achieved undetectable VL. Overall, almost
a quarter of this cohort of infected children had devel-
oped AIDS, most in the first year of life, and around
one in ten had died, at a median age of 6 months. Over-
all, survival increased significantly over the study period.
In Ukraine, ART became available for use in adults in
2001, with a somewhat slower roll-out of paediatric ART
[15]. Treatment of HIV-infected children has been a
priority of the national HIV programme, and the large-
scale provision of ART for infected individuals started in
2004. Subsequently, the proportion of children with
advanced HIV disease receiving ART increased, although
it was estimated that at least a quarter of diagnosed
children with advanced HIV disease nationally were not
receiving treatment in 2007 [6]. Our findings indicate
that more than half of the infected children had not
received HAART and of those who received it, 86% had
initiated treatment since 2007 onward. In addition, more
than a third of moderately or severely immunosuppressed
children had not yet started HAART, highlighting the
remaining unmet need for treatment.
Overall median age at HAART initiation (18 months)
was higher than reported in Western Europe [20], but
has declined substantially, to around 9 months in recent
years. This partly reflects the fact that in the early years
of the study, diagnosis of infection in vertically-exposed
infants depended on antibody testing at 15-18 months
of age, with diagnosis through PCR testing only intro-
duced in 2006. Another factor behind this trend has
been the changes in paediatric treatment protocols over
time: up to 2005, treatment of infected children was
delayed until eligibility criteria were met. Current WHO
guidance recommends treating all HIV-infected infants
aged < 12 months with HAART, on the basis of results
Table 4 Immunosuppression categories at most recent follow-up visit (N = 155)
Immunologic category Age of child at most recent follow-up visit
< 12 months 1-5 years 6-12 years
n=3 5 n=9 4 n=2 6
μL N (%) μL N (%) μL N (%)
1: No evidence of suppression > 1500 20 (57) > 1000 69 (73) > 500 22 (85)
2: Evidence of moderate suppression 750-1499 7 (20) 500-999 19 (20) 200-499 1 (4)
3: Severe suppression < 750 8 (23) < 500 6 (7) < 200 3 (11)
Figure 2 Estimated progression to death, by time period of delivery among 94 HIV-1 infected children born in 2000 to 2003 and 151
born in 2004 to 2008.
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and immunological benefits of early initiation of
HAART [7-9,21]. However, this approach requires
prompt diagnosis of infected infants and rapid commu-
nication of the result to the family and caring physi-
cians, which can be challenging in Ukraine where PCR
testing is carried out in just three regional laboratories.
Our findings highlight the importance of prompt early
d i a g n o s i si nt h i sp o p u l a t ion, as 15.5% of infants had
rapid disease progression (developed AIDS or died) in
their first year of life. Although PCR testing in Ukraine
was available, only a quarter of infected children in our
study born in 2007/08 had a PCR test before four
months of age. Despite the remaining challenges with
respect to early diagnosis of infected infants in Ukraine,
the trend towards earlier diagnosis of HIV infection we
have documented here, together with greater availability
of HAART, are likely to explain the improved estimated
survival rate among children in our cohort born in
2004/08 compared with those born earlier. Our finding
of a substantially higher rate of AIDS-free survival
among children who had never received HAART in
comparison with those treated is most likely the result
of confounding by indication, whereby children with
immunological/clinical indications and thus with poorer
s u r v i v a lp r o g n o s i sw e r em o r el i k e l yt ob ep r e s c r i b e d
H A A R T ,b u ta l s om o r el i k e l yt oh a v eo rt op r o g r e s st o
AIDS or to die. Children on HAART here showed good
virological response, and the 75% who achieved unde-
t e c t a b l ev i r a ll o a dw a ss i m i l a rt ot h a tr e p o r t e di no t h e r
studies - for example 77.5% in Italy and 78% in the UK
[20,22]. However, our results are limited by the fact that
many children had only recently started HAART and
thus had no post-initiation VL measurement available.
Cotrimoxazole is a widely available antibiotic, recom-
mended by WHO and UNAIDS for prevention of oppor-
tunistic infections in individuals living with HIV/AIDS
since April 2000 [23]. Several guidelines recommend that
cotrimoxazole should be started in all infants born to
HIV-infected mothers at 6 weeks of age, continuing until
confirmation of negative HIV status [24,25]. Results of
one trial showed a 43% reduction in mortality and a 23%
reduction in hospitalizations among HIV-infected chil-
dren receiving cotrimoxazole compared to the control
group [26]. Consequently, large-scale provision of cotri-
moxazole to all infants born to HIV-infected mothers
regardless of their age, CD4 count and resistance to the
drug in low resource countries is recommended to pre-
vent mortality and morbidity caused by PCP infection
[26]. In our study PCP was the most common AIDS-
defining disease followed by recurrent bacterial infection,
consistent with other findings in Côte d’Ivoire, Thailand,
the U.K., the U.S. and some European countries
[11,22,27-29]. However, cotrimoxazole was provided to
o n l y2 9 %o fc h i l d r e ni no u rc o h o r t .I na d d i t i o n ,t h e
majority (80%) of children who died with reported AIDS-
defining diseases had infectious diseases including PCP
but only 10% had received cotrimoxazole prophylaxis.
Despite governmental policy for free cotrimoxazole cov-
erage for HIV-infected children in Ukraine, our findings
indicate that infected children do not have adequate
access to prophylaxis; furthermore, anecdotal reports
suggest that parents will be charged for the drug’sp u r -
chase. The reason for low provision of cotrimoxazole to
prenatally HIV-exposed infants in Ukraine remains
unclear. However, anecdotal reports suggest contributing
factors may include non-availability of cotrimoxazole in
some AIDS Centers, a lack of paediatric formulations
and problems with reimbursement to parents. In order to
improve morbidity and mortality among vertically HIV
infected children, there is an urgent need for scaling-up
access to cotrimoxazole prophylaxis.
High prevalence of TB co-infection in HIV-infected
people is a well recognised problem in resource-limited
settings [30]. The incidence of TB in Ukraine was esti-
mated at 82/100,000 in 2007 [31]. Although TB has
been identified as the leading cause of death among
HIV-infected population in Ukraine [6], only 15% of
HIV-infected individuals with TB received TB treatment
in 2006 [6], reflecting old-fashioned approaches to TB
control and weak linkages between HIV and TB services
[32-34]. Children with HIV-infected parents have an
increased likelihood of TB exposure [30], mainly due to
the increased risk of acquiring TB from within their
household; HIV-infected children may also be exposed
to TB if staying on the same inpatient wards as HIV-
infected adults with active TB [34]. Infants born to
HIV-infected mothers do not receive BCG immuniza-
tion in Ukraine; infants who serorevert are eligible for
immunization but not infected children. Furthermore,
TB-HIV coinfected children in Eastern Europe often
have severe presentation of TB disease [32], In our
study co-infection with extra-pulmonary M. tuberculosis
infection was reported for 13% of children with AIDS;
however, we may have underestimated the true preva-
lence of TB in the cohort. Optimizing TB prevention,
screening and treatment strategies through integration
of HIV-TB services are essential to reduce TB related
morbidity and mortality among HIV-infected children.
We estimated that overall, 17% of children will have
progressed to AIDS or death by age 12 months, increas-
ing by only 4% over the next 6 months. This is consis-
tent with early natural history studies, which
demonstrated that 15-20% infants had an early severe
disease (opportunistic infections, especially PCP, and
encephalopathy), progressing rapidly to AIDS/death
within their first year of life, while the remainder had
more gradual disease progression, with around 3-5%
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finding of a significant improvement in AIDS-free survi-
val over time reflects the roll-out of ART for infected
children in Ukraine and the trend towards earlier diag-
nosis of infection in infants born to HIV-positive
mothers.
Nearly a fifth of the infected children here were living
in an institutional care setting. According to one
national report, one-third of HIV-infected children with
established status in Ukraine were under institutional
care by the end of July 2007 [6]. High rates of infant
abandonment have also been reported from the Russian
Federation [36,37], and in Western Europe earlier in the
HIV epidemic, usually associated with maternal IDU
and marginalised social status of many HIV-infected
women [2,38,39]. Implementation of comprehensive
PMTCT programmes may reduce risk of infant aban-
donment [2,4,40], and declining rates of abandonment
have been documented concurrent with scale-up of
PMTCT [40]. Since institutional care is associated with
detrimental affect on all aspects of infant’sd e v e l o p m e n t
and HIV-infected infants are vulnerable to stigmatised
care [37,40] strategies are needed for improving access
to antenatal and other medical and social care for hard-
to-reach pregnant women including IDUs. Furthermore,
in our young (median age of 23 months) cohort of
infected children, at least 4% had already experienced
maternal death, highlighting a need for alternative social
care for orphans and respite care for children with sick
parents.
Unsurprisingly, PMTCT prophylaxis coverage among
the mother-child pairs in this sub-cohort of infected
children was lower than that seen for the whole cohort,
which had 93% coverage in 2006 [4]; however, many of
the children here were infected despite receipt of
PMTCT prophylaxis, largely sdNVP or short-course
ZDV, which are less effective than HAART. The current
PMTCT policy in Ukraine recommends use of HAART
as PMTCT prophylaxis as well as for maternal treat-
ment, which is likely to result in a lower national
MTCT rate, although this should be considered in the
context of annually increasing numbers of HIV-infected
women delivering in Ukraine [3]. MTCT rates remain
elevated in some groups of women, particularly IDUs.
One-third of mothers here reported an IDU history,
higher than that seen in the ECS overall (around a fifth),
reflecting the increased risk of intrapartum diagnosis
and thus of MTCT among IDUs [4]. In order to achieve
further and sustainable declines in MTCT and to opti-
mise paediatric HIV treatment and care, it will be essen-
tial to implement non-stigmatised multidisciplinary
services and continue to improve the coverage and qual-
ity of PMTCT interventions.
There are several limitations to this observational
study, which has potential for both measured and
unmeasured confounding. As an observational study in
a real-life setting, there were some missing variables for
some of the children, including CD4 and VL measure-
ments. Information on adherence to therapy and viral
resistance mutations was not collected, and thus we
were unable to adjust for these potential confounders.
The short median duration of HAART by the time of
this analysis (6.6 months) is a further limitation; future
analyses of data from this cohort will allow the longer-
term impact of HAART to be addressed in addition to
the impact of HAART started at younger ages and
before progression to symptomatic disease. Follow-up of
infected children from birth prevents under-estimation
of mortality that can be a problem in non-birth cohorts
and we expect our results to be broadly generalisable to
the HIV-infected paediatric population in Ukraine.
Conclusions
In conclusion, in this large birth cohort of vertically
HIV-infected children in Ukraine, we have documented
in a “real-life”, operational setting that these children
have a good response to HAART, which is being used
earlier and more widely, reflecting the ongoing scale-up
of early infant diagnosis and paediatric treatment
nationally. The improvements in survival in more recent
years of the study reflect these trends. Further research
is needed to explore the issues of adherence, long term
exposure to HAART and subsequent adverse effects in
this population.
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